Award
NIH Reporter #5R37CA246239-07
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Recipient
Not specified
Award Amount
$351,924.00
Ceiling
$351,924.00
Awarded
January 29, 2026
Identifier
5R37CA246239-07
Award for research on enhancing checkpoint blockade immunotherapy through cross-priming tumor-reactive T cells with in situ vaccination, funded by NIH/NCI.
Description
This project involves immunology studies related to checkpoint blockade immunotherapy, in situ vaccination, and tumor-specific T cell responses. It is funded by NIH/NCI under award number 5R37CA246239-07.